EU approves Otsuka/Lundbeck's Abilify Maintena

The European Commission has given the green light to Otsuka Pharmaceutical Co and Lundbeck’s Abilify Maintena for schizophrenia.

Abilify Maintena is a once-monthly, long-acting injectable version of the oral blockbuster Abilify (aripiprazole). Specifically it has been approved as maintenance treatment of schizophrenia in adults stabilised with oral aripiprazole.

1 Like

New once-monthly treatment for schizophrenia, ABILIFY MAINTENA™ (aripiprazole for prolonged release injectable suspension), now available in Canada

Read more:


@BarbieBF do you know of
any means to find out if this injectable will be available in South Africa any time soon?

I can’t find any reference to it. Hopefully that will change soon.